Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis
compared their effectiveness and safety. Methods: We searched systematically in PubMed,
ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, EMBASE, Web of Science,
and Google Scholar for relevant clinical trials regarding gefitinib versus erlotinib for NSCLC.
Antitumor effectiveness (overall survival [OS], progression-free survival [PFS], objective …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis
compared their effectiveness and safety. Methods: We searched systematically in PubMed,
ScienceDirect, The Cochrane Library, Scopus, Ovid MEDLINE, EMBASE, Web of Science,
and Google Scholar for relevant clinical trials regarding gefitinib versus erlotinib for NSCLC.
Antitumor effectiveness (overall survival [OS], progression-free survival [PFS], objective …
以上显示的是最相近的搜索结果。 查看全部搜索结果